Development of functional cytokine mutants bymolecular evolution and drug delivery technology

DOI Web Site 27 References
  • Tsunoda Shin-ichi
    Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Science, Osaka University
  • Tsutsumi Yasuo
    Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Science, Osaka University

Bibliographic Information

Other Title
  • プロテインエンジニアリングを利用した次世代バイオ創薬　　分子進化技術によるサイトカイン機能改変体の創製とＤＤＳ
  • 分子進化技術によるサイトカイン機能改変体の創製とDDS
  • ブンシ シンカ ギジュツ ニ ヨル サイトカイン キノウ カイヘンタイ ノ ソウセイ ト DDS

Search this article

Abstract

Recently, disease-related proteinshave received attention for advanced drug therapies. Indeed, attempts are being made to develop a wide variety of therapeutic proteins for diseases including cancerand autoimmune conditions.Unfortunately, however, the utilization of bioactive proteins in clinical practice is often limited because of their inherent instability and pleiotropic actions in vivo. Our project aims to overcome two major problems, details of which will be addressed in separate sections to follow. (i) Development of a system rapidly creating functional mutant proteinswith enhanced affinityor specificitytothe receptors using a phage display technique. (ii) Establishment of apolymer-conjugation system improving in vivo stability and selectively of bioactive proteins (polymeric DDS). In this review, we introduce our DDS-based technologies for next-generation biodrug development.

Journal

  • Drug Delivery System

    Drug Delivery System 26 (6), 604-610, 2011

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(27)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top